

Could novel immune cell therapy combat hepatitis B infections?

April 10 2024



Credit: Pixabay/CC0 Public Domain

Chronic infection with the hepatitis B virus (HBV) causes progressive liver problems, and eradication of the virus remains a formidable challenge.

However, <u>new research</u> in *FEBS Letters* indicates that treatment that



boosts the effects of immune cells called stem cell memory T cells (TSCMs) may be a promising strategy for combating HBV.

In the study, investigators identified TSCMs in patients with chronic HBV infection and analyzed their effects in a mouse model of HBV. After introducing TSCMs from patients into the mice, the immune cells differentiated into cytotoxic T cells and activated a strong response that resulted in the elimination of HBV-infected liver cells. Therefore, augmenting patients' TSCMs may help the immune system overcome the virus.

"Our hepatitis model may reveal how TSCMs differentiate into cytotoxic T cells and uncover the fate of differentiated T cells. Such information could greatly advance future research on T cell-based therapies," said corresponding author Hiromi Abe-Chayama, Ph.D., of Hiroshima University, in Japan.

More information: Hepatitis B virus-specific human stem cell memory T cells differentiate into cytotoxic T cells and eradicate HBVinfected hepatocytes in mice, *FEBS Letters* (2024). DOI: <u>10.1002/1873-3468.14842</u>, <u>onlinelibrary.wiley.com/doi/10 ...</u> <u>1002/1873-3468.14842</u>

Provided by Wiley

Citation: Could novel immune cell therapy combat hepatitis B infections? (2024, April 10) retrieved 17 May 2024 from <u>https://medicalxpress.com/news/2024-04-immune-cell-therapy-combat-hepatitis.html</u>



This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.